1 Assessment of ten-year cardiovascular disease risk in Bangladesh: A comparative 2 analysis of laboratory and non-laboratory-based WHO risk prediction models

Md Mostafa Monower^{1*}, Shehab Uddin Al Abid¹, Mahfuzur Rahman Bhuiyan¹, Mohammad
 Abdullah Al Mamun¹, Sohel Reza Choudhury¹

- 5
- ¹ Department of Epidemiology & Research, National Heart Foundation Hospital & Research
 7 Institute, Dhaka, Bangladesh
- 8

9 ***Correspondence to:**

10 Dr. Md Mostafa Monower, Department of Epidemiology & Research, National Heart Foundation

- 11 Hospital & Research Institute, 26/4, Darussalam Rd, Mirpur-1, Dhaka-1216, Bangladesh.
- 12 Email: <u>dr.monower@gmail.com</u> Telephone: (8802) 58054708-12, Ex-7253
- 13

14 **Author and Co-authors:**

- 15 1. Md Mostafa Monower¹, MBBS, MPhil
- 16 ORCID iD: <u>https://orcid.org/0000-0002-1531-5633</u>
- 17 Email: <u>dr.monower@gmail.com</u>
- Shehab Uddin Al Abid¹, MBBS, MSc
- 20 ORCID iD: https://orcid.org/0000-0003-0656-0271
- 21 Email: <u>Shehababid79@gmail.com</u>
- 22
- 23 3. Mahfuzur Rahman Bhuiyan, MBBS, MPH, PGDDP
- 24 ORCID iD: https://orcid.org/0000-0001-6962-7264
- 25 Email: <u>mahfuzdoc@yahoo.com</u>
- 26
- 27 4. Mohammad Abdullah Al Mamun, MBBS, MPH
- 28 ORCID iD: <u>https://orcid.org/0000-0002-3377-1122</u>
- 29 Email: <u>abdullah.mmcm26@gmail.com</u>
- 30
- 31 5. Sohel Reza Choudhury¹, MBBS, MMedSc, PhD
- 32 ORCID iD: <u>http://orcid.org/0000-0002-7498-4634</u>
- 33 Email: <u>choudhurys@nhf.org.bd</u>
- 34
- ¹ Department of Epidemiology & Research, National Heart Foundation Hospital & Research
- 36 Institute, Dhaka, Bangladesh

38

Abstract

Objectives: This study aimed to estimate the 10-year cardiovascular diseases (CVD) risk in 39 40 Bangladeshi adults using updated 2019 WHO laboratory-based and non-laboratory-based models, identify key CVD risk determinants, and assess the agreement between two models. 41 Methods: We conducted a cross-sectional analysis of nationally representative Bangladesh 42 STEPS 2018 survey data, involving 2767 adults aged 40-69 years without prior CVDs, using 43 44 both versions of the updated 2019 WHO 10-year CVD risk prediction models. Logistic 45 regression identified determinants and model agreement was assessed using Bland-Altman Plot, concordance, and Kappa statistics with STATA version 17. 46

Results: In the laboratory-based model, 10.32% (95% CI: 8.78-12.11) of the population 47 was at elevated risk ($\geq 10\%$), while the non-laboratory-based model showed 9.25% (95% CI: 48 7.7-11.08). Males had significantly higher risk than females in both models (p < 0.0001). 49 50 Elevated 10-year CVD risk was associated with age increments of five years (OR=4.29, 95% CI: 3.48-5.30), being female (OR=0.31, 95% CI: 0.18-0.53), urban residence (OR=1.82, 51 95% CI: 1.20-2.74), residing in Dhaka division (OR=2.44, 95% CI: 1.26-4.73), and higher 52 education (OR=2.42, 95% CI: 1.06-5.51). Key metabolic factors included high waist-hip ratio 53 (OR=2.08, 95% CI: 1.22-3.52) and elevated triglycerides (OR=2.70, 95% CI: 1.65-4.41). 54 Comparing models, Bland-Altman plots showed limit of agreement (-3.16, 3.52) with mean 55 difference of 0.18, proportional bias (males: y=-0.43 + 1.11x; females: y=-0.43 + 1.16x), 56 57 Lin's Concordance Correlation Coefficient (LCCC) 0.90 (95% CI: 0.89-0.91), and a Kappa statistic of 0.69 (95%CI: 0.67-0.72). 58

Conclusion: A substantial portion of the adult Bangladeshi population is at elevated risk of a cardiovascular event within the next decade, with males at higher risk per both models. Sociodemographic, and metabolic factors indicating potential target groups for intervention. The non-laboratory-based model generally shows agreement with the laboratory-based model and can serve as an alternative in settings with limited laboratory resources, though caution is advised for high-risk individuals.

65 **Introduction**

66 Cardiovascular diseases (CVDs) stand as the leading cause of global mortality, accounting for 67 an estimated 17.9 million lives annually and constituting about 32% of all deaths 68 worldwide.[1] The majority of these fatalities occur in low and middle-income countries 69 (LMICs),[1] where challenges such as inadequate healthcare infrastructure, limited access to 70 essential services, and low health literacy intensify the impact of these burden.[2], [3] 71 Bangladesh, characterized as an LMIC, is experiencing a rapidly growing burden of CVDs, 72 propelled by demographic shifts and lifestyle changes.[4]

Early identification of at-risk populations is one of the effective strategies to prevent CVDs.[5], 73 74 [6] In this context, the World Health Organization's (WHO) updated risk prediction charts can 75 serve as a valuable tool, [7] which can identify individuals who would benefit most from 76 preventive interventions such as statin therapy.[8] These charts, revised in 2019, estimate 77 the 10-year risk of a major cardiovascular event using factors such as age, gender, blood pressure, smoking status, cholesterol level, and presence of diabetes.[9] The adaptations of 78 these models for 21 different global regions improve CVD risk prediction accuracy by 79 accommodating variations in risk factor levels and disease incidences across diverse 80 81 settings.[9] Additionally, these new models incorporate both fatal and non-fatal 82 cardiovascular outcomes, providing a more extensive assessment of CVD risk compared to 83 models that only predict mortality.[9]

84 Bangladesh aims to achieve a 25% reduction in premature mortality from non-communicable 85 diseases (NCDs) by 2025, as part of its commitment to reducing CVD impact, [10] continuing 86 and expanding upon the targets set in earlier plans.[11] For resource limited settings like Bangladesh, the revised WHO 2019 models offer a viable strategy for assessing CVD risk and 87 88 facilitating targeted interventions such as lifestyle modifications and pharmacotherapy.[6], 89 [12] These models are available in two forms: a laboratory-based version that includes 90 biochemical markers like total cholesterol and blood glucose, and a non-laboratory-based 91 version that relies on clinical and demographic information alone.[8], [9]

92 Evaluation of these models within the Bangladeshi context, the 2018 Bangladesh STEPS survey, provides a unique opportunity through its collected comprehensive data on non-93 94 communicable disease risk factors.[13] By identifying potential target groups for intervention, and by evaluating whether simpler, non-laboratory methods can substitute for lab-based 95 assessments, this study could markedly influence public health policies and patient 96 97 management strategies, not only in Bangladesh but also as an example for similar global 98 settings. In this context, this study aimed to estimate the prevalence of the 10-year 99 cardiovascular disease risk using both laboratory and non-laboratory-based models, identify the key determinants of CVD risk, particularly using the laboratory-based model, and assess 100 101 the agreement between the two models.

102 Methodology

103 Study design setting and sampling

104 This study used data from the 2018 Bangladesh STEPS survey, focusing on non-communicable diseases (NCDs). Conducted from February to May 2018, the survey employed a cross-105 sectional design with two-stage stratified cluster sampling. Of 496 initial primary sampling 106 107 units (PSUs), 495 were selected from urban and rural sectors across all eight divisions. In each PSU, 20 households were systematically chosen, and one adult was randomly selected 108 109 per household. A total of 8,185 individuals completed the interview, 7,208 completed physical 110 measurements, and 7,056 provided blood samples.[13], [14] After applying inclusion criteria 111 for age (40-69 years) and exclusion criteria for previous CVDs and missing data, the study 112 included 2,767 participants from 493 PSUs with complete datasets across all measured 113 variables (S1 Fig). Data completeness was paramount; therefore, observations with missing values were excluded from the analysis. We utilized a complete-case analysis approach, which 114 115 was justified due to the minimal impact of missing data: only 0.8% (n=22) of the data were 116 missing (SBP=1, WHR=4, BMI=2, and education level=15). This approach was not expected 117 to introduce any substantial bias, as the percentages of missing data for these variables were 118 very low.

119 Data collection

120 Data collection adhered to the WHO STEPS methodology (Version 3.2) and was conducted in 121 three phases. STEP-1 involved structured interviews to gather demographic and lifestyle risk factors such as residence, education, occupation, diet, physical activity, and tobacco use, 122 acknowledging that some degree of recall bias may still be present in self-reported data. 123 124 STEP-2 included physical measurements and blood pressure assessments. In the final phase, 125 STEP-3, blood samples were collected under aseptic conditions to ensure data accuracy and 126 reliability. Participants were required to fast for 12 hours prior to sample collection, while individuals with diabetes were advised to bring their medication and take it immediately after 127 128 the sample was collected. The detailed methodological procedure was described in the 2018 129 STEPS Bangladesh report.[13], [14]

130 Blood pressure measurements

Blood pressure was measured using "BP–BOSO–Medicus Control" digital monitor, which was validated by the German Hypertension League.[15] Participants were asked to rest for 15 minutes with uncrossed legs before measurements. Three consecutive readings were taken at three-minute intervals, and the mean of the last two was computed for analysis.[13]

135 Blood sample collection

Participants fasted overnight before their appointment for blood sample collection. During the visit, 5 ml of blood was drawn: 2 ml was allocated for serum glucose testing in a Fluorideoxalate vacutainer, and 3 ml was used for a lipid profile analysis in a standard tube. Samples were processed and transported to the NIPSOM Lab within 24 hours, with stringent cold chain.[13]

141 Biochemical analysis

Blood glucose levels were assessed using a Human® kit from Germany. TG levels were measured using Elitech® kits with controls from Humatrol/serodos®. Cholesterol levels were determined using an Elitech® kit with Humatrol® controls from Germany. All assays were conducted at the NIPSOM laboratory using a biochemistry auto analyzer (Selectra Pro M).[13]

146 Estimation of 10-year CVD risk

To estimate the 10-year risk of CVDs, we utilized the updated 2019 WHO 10-year CVD risk prediction models, which were tailored for 21 WHO epidemiological subregions and offered two versions per region-one requiring laboratory results and another not.[8], [9] Given the wide-ranging data collection in this dataset, including cholesterol measurements, we employed both the risk models, utilizing a STATA command developed by the authors of the revised WHO 2019 10-year CVD risk prediction models and tailored for Bangladesh.[16] The risk estimation was designed to calculate on various factors.

- Age: Grouped as 40–44, 45–49, 50–54, 55–59, 60–64, and 65–69 years.
- Sex: Analyzed by male and female categories.
- Smoking status: Classified participants as smokers or non-smokers.
- Systolic blood pressure (SBP): Categories included <120 mm Hg, 120–139 mm Hg,
 140–159 mm Hg, 160–179 mm Hg, and ≥180 mm Hg.
- Body mass index (BMI): BMI was calculated by dividing a respondent's weight in kilograms (kg) by the square of their height in meters (m²); <20, 20-24, 25-29, 30-34, and ≥35 kg/m².
- Total cholesterol: Laboratory measured blood cholesterol level (mmol/L).
- Diabetes: Defined by a fasting blood glucose level >126 mg/dl or current use of
 antidiabetic medication; categorized as present or absent.

The CVD risk levels were categorized into five groups indicating the percentage risk of likelihood of experiencing a fatal or non-fatal major cardiovascular event, such as myocardial infarction or stroke, over the next 10 years: <5%, 5% to <10%, 10% to <20%, 20% to <30%, and $\geq 30\%$.[8]

169 **Explanatory variables**

In this study, the outcome variable was defined based on the total CVD risk score, with a 170 171 score of $\geq 10\%$ classified as elevated CVD risk and a score of < 10% classified as lower CVD risk.[17] Potential factors associated with elevated CVD risk among the Bangladeshi 172 population were identified through a literature review and the availability of data from this 173 174 survey.[4], [18], [19] Sociodemographic variables considered included residence type (rural 175 or urban) and geographic division of the country (Barisal, Chittagong, Dhaka, Khulna, 176 Mymensingh, Rajshahi, Rangpur, and Sylhet), as well as educational attainment (no formal 177 education, primary, secondary, and more than secondary). Metabolic factors included waist hip ratio and blood triglyceride level. Central obesity was determined using waist-hip-ratio 178 thresholds of ≥ 0.90 for males and ≥ 0.85 for females.[20] A triglyceride level of ≥ 150 mg/dl 179 180 was classified as elevated.

181 Statistical analysis

Descriptive statistics were used to summarize the WHO 10-year CVD risk, stratified by gender, presenting weighted percent prevalence and 95% confidence intervals. Pearson's chi-squared test was conducted to assess the significance of differences. Variables estimating CVD risk and associated covariates were detailed by frequency, percentage, or medians with interquartile ranges (25th to 75th percentiles) as appropriate, as shown in **S1 & S2 Table**. Sampling weights were incorporated to estimate prevalence more accurately, ensuring a representative analysis of the study population.

To assess the influence of potential confounders on the association between 10-year labbased CVD risk and its determinants, a stepwise design adjusted logistic regression was performed. This model adjusted for age, sex, and socio-demographic variables (urban/rural

192 residence, division, education level), and metabolic risk factors (waist-hip ratio and 193 triglyceride level). Variables traditionally used for estimating CVD risk such as smoking status, systolic blood pressure, history of diabetes, total cholesterol, and body mass index were 194 excluded from the model, with the exception of non-modifiable factors like age and sex. 195 196 Outcomes were dichotomized, and independent variables were included methodically based 197 on literature recommendations. The associations were illustrated using odds ratios (ORs) with 198 95% confidence intervals (CIs). All statistical analyses were two-tailed, with a significance 199 level set at p < 0.05 for main effects and p < 0.001 for interaction effects. Multicollinearity was 200 assessed using the variance inflation factor (VIF), with a threshold of five indicating significant 201 multicollinearity.

202 The agreement between lab-based and non-lab-based risk charts was evaluated using Bland-203 Altman plots and Lin's concordance coefficient correlation (LCCC) for continuous CVD risk 204 scores, and Cohen's kappa for categorical CVD risk classifications. The Bland-Altman method 205 plotted the difference between lab-based and non-lab-based risk scores against their average, 206 and limits of agreement were calculated as the mean difference \pm 1.96 standard deviations 207 (SD) of the mean difference. The agreement between the laboratory-based and non-208 laboratory-based cardiovascular risk predictions was further assessed using Lin's Concordance 209 Correlation Coefficient (LCCC), which ranges from -1 to 1, with 1 indicating perfect 210 concordance. Cohen's kappa was employed to measure the categorical agreement between 211 the two risk charts, categorizing kappa values as follows: less than 0 indicating no agreement; 212 0.01 to 0.20 as slight agreement; 0.21 to 0.40 as fair agreement; 0.41 to 0.60 as moderate 213 agreement; 0.61 to 0.80 as substantial agreement; and 0.81 to 1.00 as almost perfect agreement. Data preparation and analysis were conducted using STATA version 17, ensuring 214 215 rigorous statistical examination and reproducibility of the results.

216 Ethical consideration

The protocol for the 2018 Bangladesh STEPS study was approved by the Bangladesh Medical 217 218 Research Council (BMRC). Before conducting interviews and collecting specimens, informed 219 written consent was obtained from all participants. Furthermore, in March 2023, the NCD 220 Microdata Repository of the World Health Organization (WHO) granted permission to access 221 and use the dataset. Since this research involves secondary data that was collected with prior 222 ethical approval and participant consent, no additional ethical clearance or further consent for 223 publication was required. Our study complies with the ethical guidelines for the analysis of 224 secondary data.

225 Results

The results presented in **Table 1** indicate estimated prevalence of 10-year cardiovascular 226 disease (CVD) risk, stratified by gender and assessed using both laboratory-based and non-227 228 laboratory-based revised WHO models. In the laboratory-based model, more than two-third 229 portion of the population was categorized at very low risk (<5%), but higher risk categories 230 also indicated important observations. Specifically, the prevalence of low risk (5% - <10%), moderate risk (10%-<20%), high risk (20%-<30%), and very high risk (\geq 30%) were 26.62% 231 (95% CI: 24.35-29.03), 9.49% (95% CI: 7.96-11.27), 0.81% (95% CI: 0.42-1.58), and 232 233 0.03% (95% CI: 0.01-0.12), respectively. Notably, males exhibited significantly higher 234 prevalence across these elevated risk categories compared to females (p < 0.0001).

235 Table 1: Estimated prevalence of WHO 10-year CVD risk by gender

236

Risk Model Type	Risk levels	Males (n=1452) % (95%CI)	Females (n=1315) % (95%CI)	Overall (n=2767) % (95%CI)
Laboratory based model	Very low (<5%)	49.28 (45.89-52.68)	77.95 (74.25-81.25)	63.05 (60.53-65.51)
(categorical)	Low (5%-<10%)	34.75 (31.51-38.13)	17.83 (14.97-21.11)	26.62 (24.35-29.03)
	Moderate (10%- <20%)	14.40 (11.75-17.51)	4.18 (2.85-6.07)	9.49 (7.96-11.27)
	High (20%-<30%)	1.52 (0.77-2.99)	0.04 (0.01-0.18)	0.81 (0.42-1.58)
	Very high (≥30%)	0.05 (0.01-0.22)	0	0.03 (0.01-0.12)
				p<0.0001
Laboratory based model	Low risk (<10%)	84.03 (80.91-86.73)	95.78 (93.89-97.11)	89.68 (87.89-91.22)
(binary)	Elevated risk (≥10%)	15.97 (13.27-19.09)	4.22 (2.89-6.11)	10.32 (8.78-12.11)
				p<0.0001
Non- laboratory-	Very low (<5%)	49.23 (45.85-52.61)	80.49 (77.16-83.43)	64.24 (61.73-66.68)
based model (categorical)	Low (5%-<10%)	35.56 (32.34-38.91)	16.71 (14.09-19.71)	26.50 (24.24-28.90)
	Moderate (10%- <20%)	14.11 (11.36-17.39)	2.75 (1.73-4.33)	8.65 (7.11 - 10.49)
	High (20%-<30%)	1.10 (0.56-2.19)	0.05 (0.01-0.40)	0.61 (0.31-1.16)
	Very high (≥30%)	0	0	0
				p<0.0001
Non- laboratory-	Low risk (<10%)	84.78 (81.52-87.56)	97.2 (95.62-98.22)	90.75 (88.92-92.3)
, based model (binarv)	Elevated risk (≥10%)	15.22 (12.44-18.48)	2.80 (1.78-4.38)	9.25 (7.7-11.08)
				p<0.0001

237 n = Sample size, % = weighted percentage; 95%CI = 95% confidence interval;

238 *p* < 0.05 indicates statistical significance; significance was assessed using Pearson's chi-squared test

239

Similarly, the non-laboratory-based model showed comparable patterns. The prevalence for low risk was 26.50% (95% CI: 24.24-28.90), for moderate risk was 8.65% (95% CI: 7.11-10.49), and for high risk was 0.61% (95% CI: 0.31-1.16). No individuals were recorded at the very high-risk level. This model also indicated clear gender disparities, with males consistently demonstrating higher risk levels than females (p<0.0001).

When categorizing risk into broader categories (**Table 1**), in the laboratory-based model, 246 247 10.32% (95% CI: 8.78-12.11) of the overall population was identified at elevated risk $(\geq 10\%)$, with a significant disparity between genders. Specifically, 15.97% (95% CI: 13.27-248 19.09) of males were at elevated risk, contrasted with only 4.22% (95% CI: 2.89-6.11) of 249 females showing the same level of risk. Similarly, the non-laboratory-based model 250 demonstrated that 9.25% (95% CI: 7.7-11.08) of participants were at elevated risk, with 251 males again showing a higher risk prevalence of 15.22% (95% CI: 12.44-18.48) compared 252 253 to 2.80% (95% CI: 1.78-4.38) among females. The marked gender differences in elevated risk were statistically significant in both models (p<0.0001), emphasizing the robustness of 254 these findings and indicating a significant gender-based divergence in CVD risk across the 255 256 Bangladeshi population.

Age-sex adjusted and multivariate adjusted forest plot (Fig 1) identified several associations 257 258 between sociodemographic and metabolic factors with the elevated ($\geq 10\%$) 10-year CVD risk. 259 In the multivariate adjusted model, age showed a strong association, with each five-year 260 increase in age nearly quadruples the risk (OR = 4.29, 95% CI: 3.48-5.30). There was a 261 notable difference by gender; females had lower odds compared to males (OR = 0.31, 95%262 CI: 0.18-0.53). Urban residency was associated with greater odds compared to rural residency (OR = 1.82, 95% CI: 1.20-2.74). Among divisions, Dhaka showed a higher 263 264 association (OR = 2.44, 95% CI: 1.26-4.73) relative to Barisal. Higher educational attainment 265 correlated with increased odds, with those having more than a secondary education showing 266 the highest odds (OR = 2.42, 95% CI: 1.06-5.51). Metabolic factors such as a substantially high waist-hip ratio (OR = 2.08, 95% CI: 1.22-3.52) and elevated triglyceride levels (OR =267

268 2.70, 95% CI: 1.65-4.41) were also associated with higher odds. The comparison between 269 age-sex adjusted model and multivariate adjusted model demonstrated minor variations of 270 odds ratios (ORs), indicating stable estimates upon the inclusion of additional 271 sociodemographic and metabolic factors.

Fig 1: Association of laboratory based 10-year CVD risk (≥10%) and its determinants
 Limits of agreement

The Bland-Altman plots (**Fig 2**) for the overall population and both sexes demonstrated the 274 275 level of agreement between laboratory-based and non-laboratory-based CVD risk scores. The 276 average of the two methods was plotted against their difference, with the mean difference 277 indicated by a purple line and the limits of agreement by dotted red lines at +1.96 and -1.96278 standard deviations from the mean difference. For the overall population, the mean difference 279 of 0.18 indicated that, on average, laboratory-based scores were slightly higher than non-280 laboratory-based scores. The 95% limits of agreement, ranging from -3.16 to 3.52, covered most differences and suggested reasonable agreement, considering clinical importance. For 281 males, the mean difference was 0.22 with limits of agreement from -3.51 to 3.96, showing 282 substantial variability despite general agreement. For females, the mean difference was lower 283 284 at 0.13, with narrower limits of agreement from -2.71 to 2.97, indicating slightly better consistency than in males. 285

Fig 2: Bland-Altman plots level of agreement between laboratory-based and non-laboratorybased WHO 10-year CVD risk scores (A) Overall population (B) Among males (C) Among females

Across all plots, there was a noticeable trend indicating that the discrepancy between the laboratory-based and non-laboratory-based methods increased as the average CVD risk scores rose. This proportional bias, highlighted by the regression equations (males: y=-0.43+ 1.11x; females: y=-0.43 + 1.16x), suggested that differences widened more than proportionally with rising risk scores, which was higher in females, where the regression line's steeper slope pointed to greater discrepancies at higher scores.

295 Agreement by Lin's Concordance Correlation Coefficient (LCCC)

The Lin's Concordance Correlation Coefficient (LCCC) value was found to be 0.90 (95% CI: 0.89-0.91), as shown in **Table 2**, indicating a high level of agreement between the laboratorybased and non-laboratory-based 10-year CVD risk scores. Upon stratification by sex, the LCCC was calculated at 0.89 (95% CI: 0.88-0.90) for males and 0.87 (95% CI: 0.86-0.88) for females, demonstrating similarly high agreement for both genders in the 10-year CVD risk assessments.

302 Table 2: Agreement between laboratory-based and non-laboratory-based 10-Year

303 **CVD** risk scores by Lin's concordance correlation coefficient and kappa statistic

304

Measurement	Male	Female	Overall		
Lin's Concordance Correlation Coefficient (LCCC)					
LCCC	0.89 (95%CI: 0.88-0.90)	0.87 (95%CI: 0.86-0.88)	0.90 (95%CI: 0.89-0.91)		
Kappa Statistic (C	ategorical Agreement)				
Карра	0.68 (95%CI: 0.64-0.71)	0.66 (95%CI: 0.61-0.71)	0.69 (95%CI: 0.67-0.72)		
95%CI = 95% confid	lence interval				

305 306

307 *Categorical agreement*

In the overall population, substantial agreement was observed (Table 2) between the 308 309 laboratory-based and non-laboratory-based methods when the risk scores were categorized using a five-group classification system based on different levels of CVD risk. The Kappa 310 311 statistic for the entire sample was 0.69 (95%CI: 0.67-0.72), indicating substantial agreement. When stratified by sex, the level of agreement varied; for males, the Kappa 312 statistic was 0.68 (95%CI: 0.64-0.71), and for females, the Kappa statistic was slightly lower 313 at 0.66 (95%CI: 0.61-0.71). These findings indicate that both methods generally exhibited 314 substantial agreement across the total population and both genders, suggesting that the 315 316 observed patterns are unlikely to be due to random variation.

317 Discussion

This study assessed the 10-year risk of fatal and non-fatal CVD in Bangladesh using both laboratory-based and non-laboratory-based revised WHO 2019 risk prediction models, highlighting sociodemographic and metabolic factors associated CVD risk. Moreover, the findings demonstrated the agreement between the models to underscore the similarity of estimation.

323 The laboratory-based model identified 10.32% of the population as being at elevated risk 324 $(\geq 10\%)$ (**Table 1**), slightly higher than the 9.25% identified by the non-laboratory-based 325 model. This prevalence was lower than those reported in previous studies in Bangladesh, which reported rates from 14.9% to 27.5%.[12], [17], [21], [22] Comparative studies from 326 327 other LMIC regions reported lower moderate to high CVD risk prevalence: 8.8% (laboratorybased) and 12.6% (non-laboratory-based) in Bhutan, and 8.4% (laboratory-based) and 7.5% 328 329 (non-laboratory-based) in Eastern Sub-Saharan Africa.[23], [24] Over three-fifths of the population were categorized as very low risk (<5%), and about one-fifth as low risk (5%-330 <10%), with similar patterns in both models. Although the likelihood of cardiovascular events 331 is generally lower in people with lower risk, it is crucial to understand that they are not entirely 332 333 risk-free.[25] If effective public health measures are not implemented, cardiovascular events 334 could still occur among those with lower risk categories, who make up the majority of the 335 population.[26]

The low readiness index in primary care settings, such as Upazila Health Complexes (UHCs), compared to District Hospitals (DHs), indicates that the primary healthcare system is illequipped to handle the growing burden of CVD. Facilities that offer both diagnostic and treatment services for CVDs are limited, and only a small fraction have adequately trained staff for managing these conditions.[27] The introduction of NCD corners has increased awareness and improved care for conditions like diabetes, hypertension, and chronic obstructive pulmonary disease. However, challenges persist, such as the absence of specific

343 guidelines, a shortage of trained personnel, inadequate laboratory facilities, insufficient 344 logistics and medications, and poor recording and reporting systems.[28]

345 Among the population, the impacts of both sociodemographic and metabolic determinants on CVD risk were clearly delineated in the age-sex adjusted and multivariate adjusted models. 346 Age was confirmed as a fundamental determinant, with each five-year increment nearly 347 guadrupling CVD risk, mirroring global data that underscores aging as a primary risk factor 348 349 for cardiovascular deterioration.[29] Gender differences were also evident, with females 350 displaying significantly lower risk odds compared to males, aligning with international studies that suggest hormonal protections in females and generally later onset of CVD.[30] These 351 results are consistent with global trends observed in other studies, which consistently report 352 higher CVD risk in males across various populations.[31], [32] 353

354 Urban residency was associated with higher CVD risk compared to rural, reflecting the 355 influence of urbanization on health through lifestyle changes such as increased sedentary behavior and dietary shifts towards processed foods.[19] Living in the Dhaka division was 356 also associated with CVD risk, consistent with previous research identifying stress and 357 pollution as contributing factors.[33] Surprisingly, higher educational attainment correlated 358 with increased CVD risk, contrasting with some global findings where education typically 359 360 reduces risk through improved health literacy and access to care.[34] In Bangladesh, this 361 may highlight adverse lifestyle factors associated with higher education and socio-economic 362 status, such as less physical activity and higher caloric intake.[19] Metabolic factors, including 363 waist-hip ratio and elevated triglyceride levels, were strongly linked with higher CVD risk, 364 consistent with findings from the REACTION study.[35] The robustness of these associations, demonstrated by their consistency across various model adjustments, suggests that the 365 366 association are minimally influenced by confounding factors.

367 The Bland-Altman analysis in this study explained a general agreement between laboratory-368 based and non-laboratory-based CVD risk assessment methods, with minor mean differences, 369 underscoring the role of biochemical markers in risk calculations. Furthermore, narrow limit of agreement for females indicated better consistency compared to males. These observations 370 support existing literature that validates non-laboratory methods as reliable alternatives for 371 372 CVD risk assessment, making them particularly beneficial in resource-constrained 373 environments.[23], [36] The Lin's Concordance Correlation Coefficient (LCCC) values 374 demonstrated substantial agreement (overall LCCC = 0.90), with slightly higher concordance in males. These findings confirm the consistency of both assessment methods in evaluating 375 376 CVD risk, supporting their use across various clinical and epidemiological settings. Similar 377 findings of high concordance between the two WHO CVD risk assessment methods were reported in comparative studies from Bangladesh and India.[21], [37] Moreover, the Kappa 378 379 statistics indicated substantial agreement across the total population and both genders using 380 the five-group classification system. Similarly, studies conducted in North India reported lower 381 Kappa values, whereas those in Bhutan noted higher values. [23], [37] This agreement is key for public health strategies, aiding high-risk population identification and intervention. Non-382 laboratory methods are beneficial for their simplicity and low resource needs. 383

The regression line indicated an increasing discrepancy between the two methods as average CVD risk scores rose, which was more evident in females. This trend suggests the nonlaboratory method may struggle with complex risk factors at higher CVD risk levels. Despite the general agreement and validation of non-laboratory methods as cost-effective alternatives, the observed increasing discrepancies with rising CVD risk scores in both genders necessitate cautious use, particularly for higher risk assessments among female individuals, and suggest potential benefits from complementary detailed laboratory evaluations.

391 Clinical and policy implication

392 The implications of findings from this paper are influential for both clinical practice and policy 393 development. Clinically, non-laboratory-based CVD risk scores should be used cautiously for high-risk individuals, who may require precise evaluations using laboratory-based methods. 394 From a policy perspective, integrating WHO risk prediction models into national health 395 guidelines and screening programs could effectively identify at-risk populations, supporting 396 397 cost-effective preventive strategies. Leveraging simpler, non-laboratory models for 398 widespread use, particularly in resource-limited settings, can effectively reach a broader population. Training community health workers to conduct assessments and initiate 399 preventive measures, such as providing health advice and making referrals, could further 400 democratize access to critical health services and enhancing the health resilience of the 401 Bangladeshi population.[8] 402

403 Strengths and limitations

This study used both laboratory-based and non-laboratory-based WHO updated risk 404 prediction models tailored for the Bangladeshi population, enhancing CVD risk assessment 405 406 precision. Utilizing a country representative dataset ensures findings are broadly applicable across Bangladesh. Major strengths include analysis of gender variability, sociodemographic 407 408 and metabolic determinants, and model comparison, enriching our understanding of CVD risk. 409 Despite these valuable insights, the study is subject to several limitations. Its cross-sectional 410 design limits the ability to establish causality. Self-reported data on lifestyle factors may 411 introduce recall bias. The focus on individuals aged 40-69 does not fully represent younger 412 adults increasingly affected by lifestyle-related health issues. Additionally, findings may not be generalizable to other countries due to variations in diet, lifestyle, and health infrastructure 413 414 that are specific to Bangladesh.

415 Conclusion

416 This study has demonstrated that a substantial portion of the adult Bangladeshi population is 417 at elevated risk of cardiovascular event within the next decade, with males at higher risk according to both laboratory-based and non-laboratory-based models. Moreover, the findings 418 419 have highlighted the association between sociodemographic and metabolic factors and cardiovascular health risk, indicating potential target groups for intervention. Notably, the 420 421 non-laboratory-based model have shown substantial agreement with the laboratory-based 422 model and can serve as an alternative in settings with limited laboratory resources, although 423 caution is advised for high-risk individuals.

To improve the non-laboratory-based model's accuracy at higher risk scores, future research 424 may consider incorporating accessible predictive markers like waist circumference or detailed 425 familial health histories. Regular validation and recalibration of both models through 426 427 longitudinal studies will help maintain their relevance, particularly for younger adults. Additionally, exploring how socioeconomic and biological factors interact could deepen 428 understanding of CVD risk disparities across different genders and socioeconomic groups. 429 Effective intervention strategies should also be developed, leveraging community health 430 431 initiatives, targeted educational programs, and mobile health technology.

Acknowledgements: We express our gratitude to the participants of the Bangladesh STEPS 2018 survey for their invaluable contributions. This research was made possible by the dedicated efforts of the National Institute of Preventive and Social Medicine (NIPSOM) and the Ministry of Health and Family Welfare of Bangladesh. We also thank the World Health Organization for their support and for providing access to the necessary datasets.

Author Contributions: Choudhury, Abid, and Monower conceptualized and designed the study framework. Monower conducted the statistical analysis and, along with Abid, performed the initial data interpretation. Monower drafted the initial manuscript. Bhuiyan, Mamun, Abid, Monower, and Choudhury made critical revisions for intellectual content. All authors approved the final version and agree to be accountable for all aspects of the work, ensuring questions related to accuracy or integrity are appropriately investigated and resolved.

443 **Declaration of conflict of interests:** The authors affirm that there are no conflicts of 444 interest regarding the research, authorship, or publication of this article.

445 **Funding:** No financial support was received for the conduct of this research or the preparation446 of this article.

447 **Competing interests:** There are no competing interests to declare.

Patient consent for publication: Not applicable as this study did not require direct patient
involvement; it utilized existing data from the Bangladesh STEPS 2018 survey.

Data availability statement: Data for this study were obtained from the publicly accessible datasets of the Bangladesh STEPS 2018 survey, which are available via the World Health Organization NCD Microdata Repository. The data can be accessed from the repository at the following URL: https://extranet.who.int/ncdsmicrodata/index.php/home [accessed on 21 Mar 2023]. Following the repository's instructions, the data can be downloaded.

455 References

- 456 [1] World Health Organization (WHO), 'Cardiovascular diseases (CVDs)', Geneva: World Health
 457 Organization. Accessed: Feb. 27, 2024. [Online]. Available: https://www.who.int/news458 room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- 459 [2] S. Yusuf *et al.*, 'Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries',
 460 *New England Journal of Medicine*, vol. 371, no. 9, pp. 818–827, Aug. 2014, doi:
 461 10.1056/nejmoa1311890.
- 462 [3] D. H. Peters, A. Garg, G. Bloom, D. G. Walker, W. R. Brieger, and M. Hafizur Rahman, 'Poverty and
 463 access to health care in developing countries', *Ann N Y Acad Sci*, vol. 1136, pp. 161–171, 2008,
 464 doi: 10.1196/annals.1425.011.
- 465 [4] S. J. Mumu, F. F. Stanaway, and D. Merom, 'Rural-to-urban migration, socio-economic status and
 466 cardiovascular diseases risk factors among Bangladeshi adults: A nationwide population based
 467 survey', *Front Public Health*, vol. 11, Apr. 2023, doi: 10.3389/fpubh.2023.860927.
- 468 [5] D. Zhao, J. Liu, W. Xie, and Y. Qi, 'Cardiovascular risk assessment: A global perspective', *Nat Rev*469 *Cardiol*, vol. 12, no. 5, pp. 301–311, May 2015, doi: 10.1038/nrcardio.2015.28.
- 470 [6] World Health Organization (WHO), 'WHO package of essential noncommunicable (PEN) disease
 471 interventions for primary health care', Geneva: World Health Organization, 2020. Accessed: Mar.
 472 11, 2024. [Online]. Available: https://www.who.int/publications/i/item/9789240009226
- 473 [7] World Health Organization (WHO), 'WHO updates Cardiovascular Risk Charts', Geneva: World
 474 Health Organization . Accessed: Feb. 06, 2024. [Online]. Available:
 475 https://www.who.int/news/item/02-09-2019-who-updates-cardiovascular-risk-charts#
- 476 [8] World Health Organization (WHO), 'HEARTS technical package for cardiovascular disease
 477 management in primary health care: risk based CVD management', Geneva: World Health
 478 Organization, 2020. Accessed: Feb. 19, 2024. [Online]. Available:
 479 https://www.who.ist/publications/i/team/0700240001267
- 479 https://www.who.int/publications/i/item/9789240001367
- 480 [9] S. Kaptoge *et al.*, 'World Health Organization cardiovascular disease risk charts: revised models to
 481 estimate risk in 21 global regions', *Lancet Glob Health*, vol. 7, no. 10, pp. e1332–e1345, Oct.
 482 2019, doi: 10.1016/S2214-109X(19)30318-3.
- 483 [10] Bangladesh. Directorate General of Health Services and WHO Bangladesh, 'Multisectoral Action
 484 Plan for Prevention and Control of Noncommunicable Diseases 2018-2025: with a three year
 485 operational plan.', Dhaka: Non-communicable Disease Control Programme, Directorate General
 486 of Health Services, May 2018. Accessed: Apr. 13, 2023. [Online]. Available:
- 487 ttps://www.who.int/docs/default-source/searo/ncd/ban-ncd-action-plan-2018-2025.pdf?sfvrsn
- [11] Directorate General of Health Services Ministry of Health and Family Welfare and WHO
 Bangladesh, 'Strategic Plan for Surveillance and Prevention of Non-Communicable Diseases in
 Bangladesh 2011-2015', NCD Unit Directorate General of Health Services, 2011, Accessed: Apr.
- 491 13, 2023. [Online]. Available: https://www.iccp-
- 492 portal.org/system/files/plans/Bangladesh_NCD_Strategic_Plan_2011__2015.pdf

493 J. Y. Islam, M. M. Zaman, M. Moniruzzaman, S. Ara Shakoor, and A. H. M. E. Hossain, 'Estimation [12] 494 of total cardiovascular risk using the 2019 WHO CVD prediction charts and comparison of 495 population-level costs based on alternative drug therapy guidelines: A population-based study of 496 adults in Bangladesh', BMJ Open, vol. 10, no. 7, Jul. 2020, doi: 10.1136/bmjopen-2019-035842. 497 World Health Organization, 'National STEPS Survey for Non-communicable Diseases Risk Factors [13] 498 in Bangladesh 2018', Country Office for Bangladesh, 2018. Accessed: Apr. 12, 2023. [Online]. 499 Available: https://apps.who.int/iris/handle/10665/332886 500 [14] B. K. Riaz et al., 'Risk factors for non-communicable diseases in Bangladesh: Findings of the 501 population-based cross-sectional national survey 2018', BMJ Open, vol. 10, no. 11, Nov. 2020, 502 doi: 10.1136/bmjopen-2020-041334. 503 M. M. Monower, S. U. Al Abid, A. K. Abrar, and S. R. Choudhury, 'Salt intake across the [15]

hypertension care cascade in the Bangladeshi adult population: a nationally representative cross sectional study', *BMJ Open*, vol. 14, no. 4, Apr. 2024, doi: 10.1136/bmjopen-2023-081913.

506 [16] S. Kaptoge and L. Pennells, 'University of Cambridge. Cardiovascular Epidemiology Unit.
507 Programs. World Health Organization (WHO) CVD risk score'. Accessed: Dec. 07, 2023. [Online].
508 Available: http://ceu.phpc.cam.ac.uk/software/erfc/

- [17] A. A. M. Hanif *et al.*, 'Ten-years cardiovascular risk among Bangladeshi population using non laboratorybased risk chart of the World Health Organization: Findings from a nationally
 representative survey', *PLoS ONE*, vol. 16, no. 5 May. Public Library of Science, May 01, 2021. doi:
 10.1371/journal.pone.0251967.
- 513 [18] H. Rehman *et al.*, 'Epidemiologic studies targeting primary cardiovascular disease prevention in
 514 South Asia', *Indian Heart Journal*, vol. 70, no. 5. Elsevier B.V., pp. 721–730, Sep. 01, 2018. doi:
 515 10.1016/j.ihj.2018.01.029.
- 516 [19] S. J. Mumu, A. K. M. F. Rahman, P. P. Fahey, L. Ali, and D. Merom, 'Lifestyle risk factors and
 517 metabolic markers of cardiovascular diseases in Bangladeshi ruralto-urban male migrants
 518 compared with their non-migrant siblings: A sibling-pair comparative study', *PLoS One*, vol. 17,
 519 no. 9 September, Sep. 2022, doi: 10.1371/journal.pone.0274388.
- [20] World Health Organization (WHO), 'Waist circumference and waist-hip ratio: report of a WHO
 expert consultation', Geneva: World Health Organization, 2011. Accessed: Jul. 12, 2023. [Online].
 Available: https://www.who.int/publications/i/item/9789241501491
- K. Fatema, N. A. Zwar, A. H. Milton, B. Rahman, and L. Ali, 'Application of two versions of the
 WHO/international society of hypertension absolute cardiovascular risk assessment tools in a
 rural Bangladeshi population', *Open*, vol. 5, p. 8140, 2015, doi: 10.1136/bmjopen-2015.
- 526[22]M. M. Zaman, M. Moniruzzaman, K. N. Chowdhury, S. Zareen, and A. E. Hossain, 'Estimated total527cardiovascular risk in a rural area of Bangladesh: A household level cross-sectional survey done528by local community health workers', *BMJ Open*, vol. 11, no. 8, Aug. 2021, doi: 10.1136/bmjopen-5292020-046195.

530 531 532	[23]	K. Chhezom, M. S. Gurung, and K. Wangdi, 'Comparison of Laboratory and Non-Laboratory-Based 2019 World Health Organization Cardiovascular Risk Charts in the Bhutanese Population', <i>Asia Pac J Public Health</i> , vol. 36, no. 1, pp. 29–35, Jan. 2024, doi: 10.1177/10105395231211997.
533 534 535	[24]	A. Bendera, K. Nakamura, K. Seino, and S. Alemi, 'Performance of the non-laboratory based 2019 WHO cardiovascular disease risk prediction chart in Eastern Sub-Saharan Africa', <i>Nutrition,</i> <i>Metabolism and Cardiovascular Diseases</i> , 2024, doi: 10.1016/j.numecd.2024.01.026.
536 537	[25]	J. D. Berry <i>et al.,</i> 'Lifetime Risks of Cardiovascular Disease', <i>New England Journal of Medicine</i> , vol. 366, no. 4, pp. 321–329, Jan. 2012, doi: 10.1056/NEJMoa1012848.
538 539	[26]	C. Miao <i>et al.,</i> 'Cardiovascular Health Score and the risk of cardiovascular diseases', <i>PLoS One,</i> vol. 10, no. 7, Jul. 2015, doi: 10.1371/journal.pone.0131537.
540 541 542	[27]	T. Biswas, M. M. Haider, R. Das Gupta, and J. Uddin, 'Assessing the readiness of health facilities for diabetes and cardiovascular services in Bangladesh: A cross-sectional survey', <i>BMJ Open</i> , vol. 8, no. 10. BMJ Publishing Group, 2018. doi: 10.1136/bmjopen-2018-022817.
543 544 545 546	[28]	L. B. Rawal <i>et al.</i> , 'Non-communicable disease (NCD) corners in public sector health facilities in Bangladesh: A qualitative study assessing challenges and opportunities for improving NCD services at the primary healthcare level', <i>BMJ Open</i> , vol. 9, no. 10, Oct. 2019, doi: 10.1136/bmjopen-2019-029562.
547 548 549	[29]	S. Costantino, F. Paneni, and F. Cosentino, 'Ageing, metabolism and cardiovascular disease', <i>Journal of Physiology</i> , vol. 594, no. 8. Blackwell Publishing Ltd, pp. 2061–2073, Apr. 15, 2016. doi: 10.1113/JP270538.
550 551 552	[30]	A. H. E. M. Maas and Y. E. A. Appelman, 'Gender differences in coronary heart disease', <i>Netherlands Heart Journal</i> , vol. 18, no. 12, pp. 598–603, Nov. 2010, doi: 10.1007/s12471-010- 0841-y.
553 554 555	[31]	O. Perelshtein Brezinov <i>et al.</i> , 'Gender-Related Cardiovascular Risk in Healthy Middle-Aged Adults', <i>American Journal of Cardiology</i> , vol. 118, no. 11, pp. 1669–1673, Dec. 2016, doi: 10.1016/j.amjcard.2016.08.045.
556 557 558 559	[32]	M. Walli-Attaei <i>et al.</i> , 'Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study', <i>The Lancet</i> , vol. 396, no. 10244, pp. 97–109, Jul. 2020, doi: 10.1016/S0140-6736(20)30543-2.
560 561 562	[33]	P. Joseph <i>et al.,</i> 'Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: A PURE substudy', <i>Eur Heart J</i> , vol. 43, no. 30, pp. 2831–2840, Aug. 2022, doi: 10.1093/eurheartj/ehac249.
563 564 565	[34]	N. Khan <i>et al.</i> , 'Low educational attainment is associated with higher all-cause and cardiovascular mortality in the United States adult population', <i>BMC Public Health</i> , vol. 23, no. 1, Dec. 2023, doi: 10.1186/s12889-023-15621-y.

- [35] W. Su, J. Wang, and Y. Mu, 'Association between hypertriglyceridemic waist phenotype and
 increased urinary albumin– creatinine ratio in Chinese adults: The reaction study', *Diabetes, Metabolic Syndrome and Obesity*, vol. 13, pp. 2965–2974, 2020, doi: 10.2147/DMSO.S257736.
- [36] W. C. Guzman-Vilca, G. A. Quispe-Villegas, F. F. Váscones Román, A. Bernabe-Ortiz, and R. M.
 570 Carrillo-Larco, 'Agreement between the laboratory-based and non-laboratory-based WHO
 571 cardiovascular risk charts: a cross-sectional analysis of a national health survey in Peru', *BMJ*572 *Open*, vol. 12, no. 11, Nov. 2022, doi: 10.1136/bmjopen-2022-063289.
- 573 [37] P. Ananda Selva Das, M. Dubey, R. Kaur, H. R. Salve, C. Varghese, and B. Nongkynrih, 'WHO Non574 Lab-Based CVD Risk Assessment: A Reliable Measure in a North Indian Population', *Glob Heart*,
 575 vol. 17, no. 1, 2022, doi: 10.5334/gh.1148.

576

578 Supporting information

- 579 S1 Fig: Participant selection flowchart for the Study (Total n=2767)
- 580 S1 Table: Socio-demographic characteristics of the participants
- 581 S2 Table: CVD risk factors distribution of the participants



Forest plot showing adjusted odds ratios (ORs) for sociodemographic factors (age, sex, residence, division, education) and metabolic factors (waist-hip ratio, triglycerides) associated with 10-year cardiovascular disease (CVD) risk \geq 10%, compared to reference categories or per 5-unit increase

Significant level for main effect p<0.05 and for interaction p<0.001 (n= 2767, Strata: 16, PSU: 493, population size (40-69 years): 41,543,591)

Fig 1: Association of laboratory based 10-year CVD risk (≥10%) ar







Fig 2: Bland-Altman plots level of agreeme